Sodium-glucose co-transporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor (GLP-1R) agonists, and dipeptidyl peptidase 4 (DPP-4) inhibitors showed significant benefit on cardiovascular outcomes in both patients with and without type 2 diabetes mellitus (DM) [2]. This evidence concerns the gene GLP1R and diabetes mellitus.